Interestingly, the combination of only two biomarkers (S100A9 and CA19-9) had the fourth ranking according to YI to differentiate CCA from healthy individuals (95% sensitivity, 85% specificity, AUC = 0.949, YI = 0.8, p < 0.0001). Here, S100A9 is linked to cholangiocarcinoma.